Hemostatic abnormalities in critically ill patients

Internal and Emergency Medicine

Volumn 10, Issue 3, 2015, Pages 287-296

  Levi, Marcel ^a,b   Sivapalaratnam, Suthesh ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Antifibrinolytic agents; Bleeding; Coagulation; Disseminated intravascular coagulation; Heparin induced thrombocytopenia; Intensive care; Platelets; Recombinant factor VIIa; Thrombotic microangiopathy

Indexed keywords

BLOOD CLOTTING DISORDER; COMPLICATION; CRITICAL ILLNESS; DIFFERENTIAL DIAGNOSIS; HUMAN; INFLAMMATION; INTENSIVE CARE UNIT; PROTHROMBIN TIME; THROMBOCYTOPENIA;

BLOOD COAGULATION DISORDERS; CRITICAL ILLNESS; DIAGNOSIS, DIFFERENTIAL; HUMANS; INFLAMMATION; INTENSIVE CARE UNITS; PROTHROMBIN TIME; THROMBOCYTOPENIA;

EID: 84939938879     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-014-1176-2     Document Type: Review

References (89)

1. Hunt BJ (2014) Bleeding and coagulopathies in critical care. N Engl J Med 370:847–859
2. Levi M, Schultz M (2010) Coagulopathy and platelet disorders in critically ill patients. Minerva Anestesiol 76:851–859
3. Levi M, Opal SM (2006) Coagulation abnormalities in critically ill patients. Crit Care 10:222
4. Vanderschueren S, De Weerdt A, Malbrain M et al (2000) Thrombocytopenia and prognosis in intensive care. Crit Care Med 28:1871–1876
5. Levi M, van der Poll T (2013) Endothelial injury in sepsis. Intensive Care Med 39:1839–1842
6. Ahmed A, Kojicic M, Herasevich V, Gajic O (2009) Early identification of patients with or at risk of acute lung injury. Neth J Med 67:268–271
7. Schultz MJ (2009) Early recognition of critically ill patients. Neth J Med 67:266–267
8. Strauss R, Wehler M, Mehler K et al (2002) Thrombocytopenia in patients in the medical intensive care unit: bleeding prevalence, transfusion requirements, and outcome. Crit Care Med 30:1765–1771
9. Shorr AF, Thomas SJ, Alkins SA, Fitzpatrick TM, Ling GS (2002) D-dimer correlates with proinflammatory cytokine levels and outcomes in critically ill patients. Chest 121:1262–1268
10. Bernard GR, Vincent JL, Laterre PF et al (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699–709
11. Dempfle CE, Borggrefe M (2008) Point of care coagulation tests in critically ill patients. Semin Thromb Hemost 34:445–450
12. Johansson PI, Stensballe J, Vindelov N, Perner A, Espersen K (2010) Hypocoagulability, as evaluated by thrombelastography, at admission to the ICU is associated with increased 30-day mortality. Blood Coagul Fibrinolysis 21:168–174
13. Park MS, Martini WZ, Dubick MA et al (2009) Thromboelastography as a better indicator of hypercoagulable state after injury than prothrombin time or activated partial thromboplastin time. J Trauma 67:266–275
14. Collins PW, Macchiavello LI, Lewis SJ et al (2006) Global tests of haemostasis in critically ill patients with severe sepsis syndrome compared to controls. Br J Haematol 135:220–227
15. Greaves M, Preston FE (2001) Approach to the bleeding patient. In: Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN (eds) Hemostasis and thrombosis. Basic principles and clinical practice. Lippingcott William & Wilkins, Philadelphia, pp 1031–1043
16. Edmunds LH (2001) Hemostatic problems in surgical patients. In: Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN (eds) Hemostasis and thrombosis. Basic principles and clinical practice. Lippingcott William & Wilkins, Philadelphia, pp 1031–1043
17. Bailey B, Amre DK, Gaudreault P (2003) Fulminant hepatic failure secondary to acetaminophen poisoning: a systematic review and meta-analysis of prognostic criteria determining the need for liver transplantation. Crit Care Med 31:299–305
18. Vlaar AP, Schultz MJ, Juffermans NP (2009) Transfusion-related acute lung injury: a change of perspective. Neth J Med 67:320–326
19. Mavrommatis AC, Theodoridis T, Orfanidou A et al (2000) Coagulation system and platelets are fully activated in uncomplicated sepsis. Crit Care Med 28:451–457
20. de Stoppelaar SF, van’t Veer C, van der Poll T (2014) The role of platelets in sepsis. Thromb Haemost 112:666–677
21. de Stoppelaar SF, van’t Veer C, Claushuis TA et al (2014) Thrombocytopenia impairs host defense in gram-negative pneumonia derived sepsis. Blood (in press)
22. Folman CC, Linthorst GE, van Mourik J et al (2000) Platelets release thrombopoietin (Tpo) upon activation: another regulatory loop in thrombocytopoiesis? Thromb Haemost 83:923–930
23. Francois B, Trimoreau F, Vignon P et al (1997) Thrombocytopenia in the sepsis syndrome: role of hemophagocytosis and macrophage colony-stimulating factor. Am J Med 103:114–120
24. Levi M, Lowenberg EC (2008) Thrombocytopenia in critically ill patients. Semin Thromb Hemost 34:417–424
25. Eerenberg ES, Levi M (2014) The potential therapeutic benefit of targeting ADAMTS13 activity. Semin Thromb Hemost 40:28–33
26. Moake JL (2002) Thrombotic microangiopathies. N Engl J Med 347:589–600
27. Tsai HM (2003) Platelet activation and the formation of the platelet plug: deficiency of ADAMTS13 causes thrombotic thrombocytopenic purpura. Arterioscler Thromb Vasc Biol 23:388–396
28. van den Born BJ, van der Hoeven NV, Groot E et al (2008) Association between thrombotic microangiopathy and reduced ADAMTS13 activity in malignant hypertension. Hypertension 51:862–866
29. Stephan F, Hollande J, Richard O et al (1999) Thrombocytopenia in a surgical ICU. Chest 115:1363–1370
30. Warkentin TE, Aird WC, Rand JH (2003) Platelet-endothelial interactions: sepsis, HIT, and antiphospholipid syndrome. Hematology 14:497–519
31. Verma AK, Levine M, Shalansky SJ, Carter CJ, Kelton JG (2003) Frequency of heparin-induced thrombocytopenia in critical care patients. Pharmacotherapy 23:745–753
32. Warkentin TE (2003) Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 121:535–555
33. Levi M, van der Poll T (2008) The role of natural anticoagulants in the pathogenesis and management of systemic activation of coagulation and inflammation in critically ill patients. Semin Thromb Hemost 34:459–468
34. Levi M, Nieuwdorp M, van der Poll T, Stroes E (2008) Metabolic modulation of inflammation-induced activation of coagulation. Semin Thromb Hemost 34:26–32
35. Griffin JH, Fernandez JA, Gale AJ, Mosnier LO (2007) Activated protein C. J Thromb Haemost 5(Suppl 1):73–80
36. Esmon CT (2001) Role of coagulation inhibitors in inflammation. Thromb Haemost 86(1):51–56
37. Levi M, de Jonge E, van der Poll T (2001) Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation. Crit Care Med 29(7 Suppl):S90–S94
38. Esmon CT (1987) The regulation of natural anticoagulant pathways. Science 235:1348–1352
39. Esmon CT (2000) The endothelial cell protein C receptor. Thromb Haemost 83:639–643
40. Mesters RM, Helterbrand J, Utterback BG et al (2000) Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications. Crit Care Med 28:2209–2216
41. Vary TC, Kimball SR (1992) Regulation of hepatic protein synthesis in chronic inflammation and sepsis. Am J Physiol 262:C445–C452
42. Eckle I, Seitz R, Egbring R, Kolb G, Havemann K (1991) Protein C degradation in vitro by neutrophil elastase. Biol Chem Hoppe Seyler 372:1007–1013
43. Nawroth PP, Stern DM (1986) Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 163:740–745
44. Faust SN, Levin M, Harrison OB et al (2001) Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 345:408–416
45. Taylor FBJ, Stearns-Kurosawa DJ, Kurosawa S et al (2000) The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood 95:1680–1686
46. Levi M, van der Poll T, Buller HR (2004) Bidirectional relation between inflammation and coagulation. Circulation 109:2698–2704
47. Fuchs TA, Brill A, Wagner DD (2012) Neutrophil extracellular trap (NET) impact on deep vein thrombosis. Arterioscler Thromb Vasc Biol 32:1777–1783
48. Andrews RK, Arthur JF, Gardiner EE (2014) Neutrophil extracellular traps (NETs) and the role of platelets in infection. Thromb Haemost 112:659–665
49. Saffarzadeh M, Juenemann C, Queisser MA et al (2012) Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones. PLoS One 7:e32366
50. Kowalska MA, Zhao G, Zhai L et al (2013) Modulation of protein C activation by histones, platelet factor 4, and heparinoids: new insights into activated protein C formation. Arterioscler Thromb Vasc Biol 34(1):120–126
51. Wildhagen KC, de Garcia FP, Reutelingsperger CP et al (2013) Non-anticoagulant heparin prevents histone-mediated cytotoxicity and improves survival in sepsis. Blood 123(7):1098–1101
52. Levi M (2014) The dual face of heparin in severe infection. Blood 123:947–948
53. Levi M, van der Poll T (2014) A short contemporary history of disseminated intravascular coagulation. Semin Thromb Hemost 40:874–880
54. Levi M, ten Cate H (1999) Disseminated intravascular coagulation. N Engl J Med 341:586–592
55. Levi M (2014) Diagnosis and treatment of disseminated intravascular coagulation. Int J Lab Hematol 36:228–236
56. Levi M (2014) Cancer-related coagulopathies. Thromb Res 133(Suppl 2):S70–S75
57. Levi M, Schultz M, van der Poll T (2013) Sepsis and thrombosis. Semin Thromb Hemost 39:559–566
58. Wheeler AP, Bernard GR (1999) Treating patients with severe sepsis. N Engl J Med 340:207–214
59. Levi M, Schouten M, van der Poll T (2008) Sepsis, coagulation, and antithrombin: old lessons and new insights. Semin Thromb Hemost 34:742–746
60. Levi M, Toh CH, Thachil J, Watson HG (2009) Guidelines for the management of disseminated intravascular coagulation. Br J Haematol 145:24–33
61. Taylor FBJ, Toh CH, Hoots WK, Wada H, Levi M (2001) Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 86:1327–1330
62. Dhainaut JF, Yan SB, Joyce DE et al (2004) Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2:1924–1933
63. Wada H, Gabazza EC, Asakura H et al (2003) Comparison of diagnostic criteria for disseminated intravascular coagulation (DIC): diagnostic criteria of the International Society of Thrombosis and Hemostasis and of the Japanese Ministry of Health and Welfare for overt DIC. Am J Hematol 74:17–22
64. Gando S, Saitoh D, Ogura H et al (2013) A multicenter, prospective validation study of the Japanese Association for Acute Medicine disseminated intravascular coagulation scoring system in patients with severe sepsis. Crit Care 17:R111
65. Levi M (2013) Another step in improving the diagnosis of disseminated intravascular coagulation in sepsis. Crit Care 17:448
66. Chitlur M, Rivard GE, Lillicrap D et al (2014) Recommendations for performing thromboelastography/thromboelastometry in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost 12:103–106
67. Haase N, Ostrowski SR, Wetterslev J et al (2014) Thromboelastography in patients with severe sepsis: a prospective cohort study. Intensive Care Med (in press)
68. Ranucci M, Baryshnikova E, Colella D (2012) Monitoring prohemostatic treatment in bleeding patients. Semin Thromb Hemost 38:282–291
69. Spahn DR, Bouillon B, Cerny V et al (2013) Management of bleeding and coagulopathy following major trauma: an updated European guideline. Crit Care 17:R76
70. Hellstern P, Muntean W, Schramm W, Seifried E, Solheim B (2002) Practical guidelines for the clinical use of plasma. Thromb Res 107(Suppl 1):S53
71. Hirsh J, Heddle N, Kelton JG (2004) Treatment of heparin-induced thrombocytopenia: a critical review. Arch Intern Med 164:361–369
72. Mannucci PM, Levi M (2007) Prevention and treatment of major blood loss. N Engl J Med 356:2301–2311
73. Henry DA, Carless PA, Moxey AJ et al (2011) Anti-fibrinolytic use for minimising perioperative blood transfusion. Cochrane Database Syst Rev 3:CD1886
74. Mannucci PM (1997) Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 90:2515–2521
75. Levi M, Cromheecke ME, de Jonge E et al (1999) Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet 354:1940–1947
76. Porte RJ, Molenaar IQ, Begliomini B et al (2000) Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomised double-blind study. EMSALT Study Group. Lancet 355(9212):1303–1309
77. Shakur H, Roberts I, Bautista R et al (2010) Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 376:23–32
78. Hunt BJ (2015) The current place of tranexamic acid in the management of bleeding. Anaesthesia 70(Suppl 1):50-e18
79. Levi M, Levy JH, Andersen HF, Truloff D (2010) Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 363:1791–1800
80. Warren BL, Eid A, Singer P et al (2001) Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 286:1869–1878
81. Kienast J, Juers M, Wiedermann CJ et al (2006) Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 4:90–97
82. Iba T (2014) Controversies regarding the use of antithrombin for sepsis-associated disseminated intravascular coagulation: an update of the evidence. Blood Transfus (in press)
83. Iba T, Saitoh D, Wada H, Asakura H (2014) Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: a secondary survey. Crit Care 18:497. doi:10.2450/2014.0164-14
84. Tagami T, Matsui H, Horiguchi H, Fushimi K, Yasunaga H (2014) Antithrombin and mortality in severe pneumonia patients with sepsis-associated disseminated intravascular coagulation: an observational nationwide study. J Thromb Haemost 12:1470–1479
85. Ranieri VM, Thompson BT, Barie PS et al (2012) Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 366:2055–2064
86. Saito H, Maruyama I, Shimazaki S et al (2007) Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 5:31–41
87. Aikawa N, Shimazaki S, Yamamoto Y et al (2011) Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock. 35:349–354
88. Tagami T, Matsui H, Horiguchi H, Fushimi K, Yasunaga H (2014) Recombinant human soluble thrombomodulin and mortality in severe pneumonia patients with sepsis-associated disseminated intravascular coagulation: an observational nationwide study. J Thromb Haemost. doi:10.1111/jth.12786
89. Vincent JL, Ramesh MK, Ernest D et al (2013) A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med 41:2069–2079